ROKFOS 5MG

Rokfos 5mg Injection 100ml contains zoledronic as its active ingredient. This medication falls under the category of bisphosphonates. It is utilized to lower elevated calcium levels in the blood of adult patients, particularly when these levels are heightened due to tumors. Tumors can disrupt normal bone metabolism, leading to increased calcium release from the bones. This condition is referred to as tumor-induced hypercalcemia (TIH). Additionally, it is employed to prevent bone complications in adult patients suffering from multiple myeloma and bone metastases resulting from solid tumors, alongside standard cancer treatments.

Rokfos 5mg Injection 100ml is also prescribed to prevent or treat osteoporosis, a condition characterized by fragile and weak bones that are prone to fractures, in postmenopausal women. Furthermore, it is indicated for the treatment of osteoporosis in men. It is effective in managing Paget’s disease of bone, a disorder where bones become soft, weak, and may become deformed, painful, or easily fractured. Other applications include the treatment or prevention of osteoporosis in both men and women who are on glucocorticoids, a type of corticosteroid medication that can lead to osteoporosis.

This injection should not be administered if you have an allergy to zoledronic, any other bisphosphonate, or any components of this medication, and it is contraindicated during pregnancy or breastfeeding. Prior to starting treatment, it is essential to inform your healthcare provider if you have any kidney or liver issues, bone disorders, pain, swelling, or numbness in the jaw. This medication is not advised for use in adolescents and children under 18 years of age. It is important to note that zoledronic is not a cancer chemotherapy agent and will not impede or halt cancer progression. However, it can be beneficial in treating bone diseases in cancer patients.